结果治疗后发现中西结合研究组患者的效果要比对照组高且患者没有不良反应。
Results After treatment, the study group found that WM effects than patients in the control group and patients with high no adverse reactions.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
结果经过治疗后，心律平组的疗效优于异搏定组，且不良反应率低。
Results After treatment, propafenone group, the better Isoptin group, and the low rate of adverse reactions.
应用推荐